Instil Bio, Inc. (TIL)
| Market Cap | 2.77B |
| Revenue (ttm) | 138,000 |
| Net Income (ttm) | -37.74M |
| Shares Out | 125.81M |
| EPS (ttm) | -0.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 9 |
| Last Price | $22.03 |
| Previous Close | $22.24 |
| Change ($) | -0.21 |
| Change (%) | -0.94% |
| Day's Open | 22.22 |
| Day's Range | 21.45 - 23.25 |
| Day's Volume | 122,214 |
| 52-Week Range | 21.44 - 29.49 |
DALLAS, March 23, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies f...
Last week was a busy one for the IPO market with 11 IPOs raising $3 billion, joined by 24 SPACs that brought another $8.4 billion to the table. Chinese IoT platform developer Tuya Inc (NYSE: TUYA) raise...
DALLAS, March 18, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies f...
Instil Bio, an early stage biotech developing cell therapies for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Instil Bio, Inc. has filed to go public with an IPO on the NASDAQ.
About TIL
Instil Bio is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. Using our optimized and scalable manufacturing process, we are advancing our lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma. We plan to submit an investigational new drug application, or IND, to the FDA, and, if authorized to proceed, initiate a Phase 2 trial in the second half of 2021. We plan to ... [Read more...]
| Industry Biological Products | IPO Date Mar 19, 2021 |
| CEO Bronson Crouch | Employees 150 |
| Stock Exchange NASDAQ | Ticker Symbol TIL |